Introduction {#s1}
============

Environmental exposure to the toxic metal lead (Pb) remains a public health problem. Despite a considerable decrease in lead exposure in the last two decades, there are still reports of health effects in children and adults even at low levels of exposure ([@c36]; [@c46]). Exposure to lead occurs mainly via contaminated food, drinking water, and dust but also through smoking and industrial and combustion emissions ([@c11]; [@c46]). Most of the absorbed lead is stored for decades in bones ([@c5]; [@c44]; [@c46]), and so bone lead mirrors both long-term exposure and body burden. Lead in blood (B-Pb) reflects more recent exposure, as well as the whole body burden, and is the most commonly used biomarker of lead exposure ([@c4]; [@c46]).

Cardiovascular diseases continue to be the leading cause of death and the largest contributor to premature mortality worldwide ([@c17]). In particular, ischemic heart disease and cerebrovascular disease account for nearly 10 million and 5 million deaths globally every year, respectively ([@c17]). Lead exposure is associated with an increased incidence of cardiovascular disease ([@c11]; [@c33]; [@c36]; [@c46]) and has been estimated to account for at least 240,000 ischemic heart disease deaths per year globally ([@c16]). Evidence on lead toxicity in the cardiovascular system is particularly extensive with regard to the link between lead exposure and increased blood pressure and hypertension even at concentrations $< 100\;\mu g/L$ ([@c33]; [@c36]; [@c51]). However, the impact of lead on the cardiovascular system is not restricted to effects on blood pressure. There is an increasing body of evidence suggesting an association between low-level lead exposure (concentrations $< 50\;\mu g/L$) and clinical cardiovascular outcomes such as peripheral arterial disease, cardiovascular mortality, and coronary heart disease ([@c23]; [@c33]; [@c36]; [@c46]).

Atherosclerosis has been suggested to be one of the underlying mechanisms for the cardiovascular toxicity of lead ([@c23]; [@c52]), and there are findings from experimental studies to support this ([@c14]; [@c55]). Evidence from epidemiological studies showing an association between low-level lead exposure and clinical cardiovascular outcomes also suggests atherosclerotic changes ([@c23]; [@c33]; [@c36]; [@c46]). However, we found no epidemiological studies showing an association between environmental lead exposure and the incidence or presence of atherosclerotic plaques. In the present study, we aimed to assess the association between B-Pb and prevalence of atherosclerotic plaque in the carotid artery in a Swedish population-based cohort.

Methods {#s2}
=======

Study Design and Population {#s2.1}
---------------------------

This study was based on cross-sectional baseline data from the cardiovascular cohort of the Malmö Diet and Cancer Study (MDCS-CC) ([@c40], [@c41]). The MDCS-CC is a random sample of the larger population-based Malmö Diet and Cancer Study (MDCS) ([@c6]; [@c27]), and comprises 6,103 individuals 46--67 years of age living in Malmö, Sweden, between 1991 and 1994 ([@c40]) who were selected for a substudy on the epidemiology of carotid artery disease. The present study included all individuals for whom data were available on ultrasound-assessed plaque status in the carotid artery and B-Pb ($n = 4,172$; [Figure 1](#f1){ref-type="fig"}).

![Cohort diagram illustrating the study population. The reason for missing blood lead concentrations in 1,199 participants was lack of blood sample available in the biobank for lead analysis. The lack of ultrasound-assessed plaque status in the carotid artery in 169 participants was due to technical difficulties.](ehp-127-127002-g001){#f1}

The study was carried out in accordance with the Declaration of Helsinki. MDCS-CC was approved by the Ethics Committee of Lund University, Lund, Sweden (MDCLU51--90). All participants provided informed consent.

Analyses of Lead Concentrations in Blood {#s2.2}
----------------------------------------

Venous blood samples were collected at baseline after overnight fast. Plasma and erythrocytes were separated, and lead was measured in erythrocytes using inductively coupled plasma mass spectrometry with an octopole reaction system in helium mode (Agilent 7700x ICP-MS; Agilent Technologies) at the Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden ([@c15]; [@c20]). Lead in whole blood was then calculated by multiplying the metal concentrations in erythrocytes by the hematocrit. None of the samples were below the limit of detection, which was $0.16\;\mu g/L$. External quality control samples with low lead levels (Seronorm Trace Elements Whole Blood L-1, Lot no. 1103128; Sero AS) were included in all analytical rounds and showed satisfactory results: $\text{mean} \pm \text{standard\  \ deviation}$ (SD) $10.3 \pm 0.5\;\mu g/L$ vs. recommended limits of $6–14\;\mu g/L$. The imprecision (coefficient of variation) was 5.1%, calculated from duplicate samples.

Measurement of Atherosclerotic Plaque in the Carotid Artery {#s2.3}
-----------------------------------------------------------

B-mode ultrasonography (Acuson 128 CT System; Siemens) of the right carotid artery was performed to assess plaque occurrence according to a standardized protocol, by trained, certified sonographers ([@c40]). In brief, the bifurcation area of the right common carotid artery was scanned within a predefined window comprising $3\;{cm}$ of the distal common carotid artery, the bifurcation, and $1\;{cm}$ of the internal and external carotid artery, respectively, for the occurrence of plaques. Plaque was defined as a focal thickening of the intima--media complex $> 1.2\;{mm}$ with an area $\geq 10{\,{mm}}^{2}$. Methods of quality control were used as described previously ([@c40]). The reliability of the measurements was assured by regularly (about every 3 weeks) performing intra- and interobserver variability analyses during the ultrasound investigation procedure ([@c40]). Previous intra- and interobserver analyses have been reported elsewhere ([@c38]). Intra-observer variability for three ultrasound operators were 10%, 6%, and 10%, respectively for intima--media thickness of the common carotid artery (IMT CCA). Interobserver variability of the IMT CCA for three pairs of observers was $r = 0.66$, $r = 0.94$, and $r = 0.87$, respectively.

Cardiovascular Risk Factors {#s2.4}
---------------------------

All participants filled in a self-administered questionnaire at baseline concerning lifestyle, health, occupation, and medication ([@c40]). Participants were categorized into never or ever (including both current and former) smokers. Menopausal status of women was assessed using both questionnaire data and medical records. A woman was classified as postmenopausal if *a*) she had undergone bilateral oophorectomy (medical records, $n = 45$), or *b*) the above criteria was missing and she confirmed that her menstruation had ceased $\geq 2\; y$ prior to baseline (questionnaire, $n = 1,797$), or *c*) the above criteria were absent and she was $\geq 55$ years of age ($n = 20$). Pack-years of smoking were calculated from years of smoking and the amount of tobacco smoked daily in the subgroup with such data available ($n = 3,422$ of which 1,744 were former and current smokers) ([@c13]). Daily alcohol intake was calculated in grams per day. Blood pressure, height, weight, and waist circumference were measured, and body mass index (BMI) was calculated. Hypertension was defined as an average systolic blood pressure $\geq 140\text{ \ mmHg}$ or diastolic blood pressure $\geq 90\text{ \ mmHg}$ and/or current use of antihypertensive medication prescribed by a physician. Participants were classified as having diabetes mellitus if they reported the diagnosis in the questionnaire, used anti-diabetic medication, or had a fasting venous whole blood glucose level of $\geq 6.1\text{ \ mmol}/L$. Educational level was classified as low if participants had completed $< 9\; y$ of education (i.e., had not completed secondary education). Low physical activity was defined as the lowest quartile of a summary score of physical activity based on a composite measure of 18 different leisure-time activities during the preceding year, involving information on activity intensity and time spent on the activity ([@c24]). Information on occupation was obtained from the baseline questionnaire and the most recent occupation was considered at the time of the baseline examination. The occupations were coded according to the job classification scheme Population and Housing Census from 1980 (FoB-80) and thereafter classified into blue-collar, white-collar, or self-employed workers ([@c40]). Overnight fasting blood samples were drawn for determination of hemoglobin A1c (HbA1c), whole blood glucose, high sensitivity C-reactive protein (hsCRP), high density lipoprotein (HDL), total cholesterol, low density lipoprotein (LDL), and triglycerides ([@c13]).

Statistical Analyses {#s2.5}
--------------------

Statistical analyses were performed with Stata (release 14.1; Stata Corporation). A two-tailed $p < 0.05$ was considered statistically significant. Initial bivariate associations between B-Pb and cardiovascular risk factors and potential confounders were assessed with Spearman's rank correlation ($r_{s}$) for continuous variables and the Mann-Whitney test for categorical variables. Bivariate associations between plaque prevalence and cardiovascular risk factors and potential confounders were assessed using the Mann-Whitney *U* test for continuous variables and the chi-square test for categorical variables.

Descriptive statistics were calculated by quartiles of B-Pb and presented as median (range) for nonnormal distributed variables, $\text{mean} \pm \text{SD}$ for normally distributed variables, and proportions for categorical variables. Differences across quartiles of B-Pb were tested using the Kruskal-Wallis *H* rank test for continuous variables and the chi-square test for categorical variables.

Associations between B-Pb and plaque prevalence were analyzed using multivariable-adjusted logistic regression analyses with B-Pb in quartiles. As well as a crude model (Model 1), we used an adjusted model (Model 2) that included variables associated with both B-Pb and occurrence of plaque: age (years), sex (female vs. male), smoking (never, former, or current), hypertension (yes vs. no), and waist circumference (in centimeters). A final model (Model 3) was additionally adjusted for other confounders and known cardiovascular risk factors as well as factors that may be in the pathway of B-Pb and atherosclerosis: HbA1c (as a proxy for degree of glucose intolerance), total cholesterol/HDL ratio, statin treatment (yes vs. no), hsCRP, low education level ($\leq \text{ \ vs.\  } > 9\; y$), and physical activity (low vs. high). We performed complete case analyses for each model.

Initially, we examined the associations in all individuals. Subsequently, we used multiplicative interaction terms using B-Pb in quartiles and the stratifying factor (i.e., smoking status (never/ever smokers), hypertension (no/yes), menopausal status (pre-/postmenopausal), and estimated glomerular filtration rate (eGFR) categories ($> 90$, 60--90, and $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$) and report the $p_{\text{interaction}}$ term of Q4 vs. Q1 and the highest category of the stratification factor. We then stratified the models by these factors to assess potential effect modification. Linear trend *p*-values were derived by modeling the median value of each B-Pb quartile as a continuous variable in the models.

We evaluated nonlinearity both by introducing a quadratic term for B-Pb levels in Model 3 as well as by estimating the smoothed exposure--response relationship between B-Pb levels (with and without log-transformation) and plaque (adjusted for the same covariates as Model 3), in all individuals as well as separately in men and women, using generalized additive models with the procedure gam in the mgcv package in R (version 3.3.2; R Development Core Team), where the smooth term was represented using a penalized regression spline (with 1.285 equivalent degrees of freedom). Figures show the log(odds) relabeled to odds ratios (ORs).

We performed several sensitivity analyses. We adjusted the models for pack-years instead of smoking status. We categorized pack-years in five categories: one for never-smokers (Category 1: 0 pack-years) and four based on quartiles among ever-smokers (Category 2: $> 0$ but $< 7\text{ \ pack-years}$, Category 3: $\geq 7$ but $< 16.3\text{ \ pack-years}$, Category 4: $\geq 16.3$ but $< 30\text{ \ pack-years}$, and Category 5: $\geq 30\text{ \ pack-years}$). We tested the influence of kidney function in the associations using serum creatinine eGFR ([@c20]). We included blood cadmium in adjusted models as an additional potential confounder ([@c7]; [@c13]). We adjusted Model 3 additionally for an alternative indicator of socioeconomic status, namely occupation (blue-collar, white-collar, and self-employed workers). We also adjusted Model 3 for diabetes (yes/no) instead of HbA1c as well as for BMI instead of waist circumference. In order to assess whether the associations seen among postmenopausal women were driven and explained by age, we performed stratified analyses by age ($< \text{ \ or\  } \geq 55\; y$). We also performed the regressions again using B-Pb as a continuous variable instead of in quartiles and, finally, we excluded individuals with B-Pb $> 100\;\mu g/L$ in these analyses to assess whether the associations between B-Pb (as continuous variable) and atherosclerosis were driven by individuals with very high lead levels.

Results {#s3}
=======

Cohort Characteristics {#s3.1}
----------------------

Characteristics of all MDCS-CC participants by quartiles of B-Pb are presented in [Table 1](#t1){ref-type="table"}. The median B-Pb was $25\;\mu g/L$ (range: 1.5--258; see Figure S1A). Alcohol intake, blood cadmium and waist circumference as well as the proportion of men, current smokers, self-employed workers, and individuals with hypertension were higher in the highest quartile (Q4) of B-Pb as compared with the three lowest quartiles (Q1--Q3). On the contrary, the proportion of blue-collar workers decreased with increasing quartiles of B-Pb. Both systolic and diastolic blood pressure increased with increasing quartiles of B-Pb.

###### 

Characteristics of the study participants by quartiles (Q1--Q4) of blood lead in the Malmö Diet and Cancer Study--Cardiovascular Cohort (MDCS-CC).

Table 1 has seven columns, namely, characteristics, overall, q1, q2, q3, q4, and p-value. Q1 to 4 fall under quartiles of blood lead.

  Characteristics[^*a*^](#TF2){ref-type="table-fn"}                        Overall             Quartiles of blood lead                                                            
  ------------------------------------------------------------------------ ------------------- ------------------------- ------------------ ------------------ ------------------ -----------
  Plaque occurrence in carotid artery                                      1,482 (36)          317 (30.5)                370 (35.5)         368 (35.3)         427 (40.8)         $< 0.001$
  Blood lead ($\mu g/L$)                                                   25 (1.5--258)       15 (1.5--18)              21 (18--25)        28 (25--33)        42 (33--258)       $< 0.001$
  Age (y)                                                                  $57 \pm 5.9$        $57 \pm 6.2$              $58 \pm 5.8$       $57 \pm 5.8$       $57 \pm 5.7$       0.30
  Sex                                                                                                                                                                             $< 0.001$
   Male                                                                    1,651 (40)          227 (22)                  348 (33)           472 (45)           604 (58)           
   Female                                                                  2,521 (60)          813 (78)                  694 (67)           572 (55)           442 (42)           
  Menopausal status                                                                                                                                                               0.003
   Premenopausal                                                           652 (26)            246 (30)                  168 (24)           142 (25)           96 (22)            
   Postmenopausal                                                          1,862 (74)          564 (70)                  526 (76)           427 (75)           345 (78)           
  Blood cadmium ($\mu g/L$)                                                0.26 (0.034--5.1)   0.22 (0.04--4.2)          0.24 (0.06--4.3)   0.28 (0.04--4.8)   0.33 (0.03--5.1)   $< 0.001$
  Low education level                                                                                                                                                             0.056
   Yes                                                                     1,929 (46)          499 (48)                  507 (49)           466 (45)           457 (44)           
   No                                                                      2,233 (54)          541 (52)                  530 (51)           577 (55)           585 (56)           
  Low physical activity                                                                                                                                                           0.54
   Yes                                                                     953 (23)            231 (23)                  244 (24)           227 (22)           251 (25)           
   No                                                                      3,118 (77)          782 (77)                  775 (76)           796 (78)           765 (75)           
  Body mass index (${{kg}/m}^{2}$)                                         $26 \pm 3.8$        $26 \pm 4.3$              $26 \pm 3.9$       $25 \pm 3.5$       $25 \pm 3.5$       0.96
  Waist circumference (cm)                                                 $83 \pm 13$         $81 \pm 13$               $82 \pm 13$        $84 \pm 12$        $85 \pm 12$        $< 0.001$
  Smoking status                                                                                                                                                                  
   Never-smokers                                                           1,678 (40)          532 (51)                  479 (46)           364 (35)           303 (29)           $< 0.001$
   Former smokers                                                          1,404 (34)          331 (32)                  314 (30)           401 (38)           358 (34)           $< 0.001$
   Current smokers                                                         1,090 (26)          177 (17)                  249 (24)           279 (27)           385 (37)           $< 0.001$
  Pack-years[^*c*^](#TF4){ref-type="table-fn"}                             17 (0.06--158)      14.4 (0.1--140)           15 (0.2--93)       16 (0.1--145)      20 (0.06--158)     $< 0.001$
  Alcohol consumption (g/d)                                                6.8 (0--105)        3.0 (0--44)               5.3 (0--80)        8.3 (0--86)        13 (0--105)        $< 0.001$
  Hypertension                                                                                                                                                                    $< 0.001$
   Yes                                                                     2,614 (63)          645 (62)                  619 (59)           639 (61)           711 (68)           
   No                                                                      1,558 (37)          395 (38)                  423 (41)           405 (39)           335 (32)           
  Systolic blood pressure (mmHg)                                           $140 \pm 19$        $140 \pm 18$              $139 \pm 18$       $141 \pm 19$       $142 \pm 19$       0.0036
  Diastolic blood pressure (mmHg)                                          $87 \pm 9.2$        $86 \pm 8.7$              $86 \pm 9.2$       $87 \pm 9.2$       $88 \pm 9.7$       $< 0.001$
  Diabetes mellitus                                                                                                                                                               0.31
   Yes                                                                     310 (7.4)           91 (8.8)                  71 (6.8)           73 (7.0)           75 (7.2)           
   No                                                                      3,862 (92.6)        949 (91.2)                971 (93.2)         971 (93.0)         971 (92.8)         
  Statin treatment                                                                                                                                                                0.76
   Yes                                                                     58 (1.4)            13 (1.3)                  16 (1.5)           17 (1.6)           12 (1.2)           
   No                                                                      4,114 (98.6)        1,027 (98.7)              1,026 (98.5)       1,027 (98.4)       1,034 (98.8)       
  Total cholesterol/HDL ratio                                              $4.7 \pm 1.5$       $4.7 \pm 1.5$             $4.7 \pm 1.4$      $4.8 \pm 1.5$      $4.8 \pm 1.5$      0.11
  HbA1c (%)                                                                4.8 (3.3--12)       4.7 (3.5--12)             4.8 (3.3--11)      4.7 (3.3--12)      4.8 (3.5--12)      0.021
  hsCRP (mg/mL)                                                            1.3 (0.09--60)      1.3 (0.09--60)            1.3 (0.09--56)     1.4 (0.09--53)     1.4 (0.09--58)     0.054
  $\text{eGFR}_{\text{cr}}$ (${mL}/\text{min\  \ per\  }1{.73\; m}^{2}$)   $76 \pm 14$         $76 \pm 14$               $75 \pm 14$        $76 \pm 13$        $76 \pm 14$        0.21
  Occupation                                                                                                                                                                      
   Blue-collar workers                                                     1,571 (38)          439 (43)                  413 (40)           369 (36)           350 (34)           $< 0.001$
   White-collar workers                                                    2,157 (52)          524 (51)                  541 (52)           556 (54)           536 (51)           0.64
   Self-employed workers                                                   420 (10)            68 (7)                    84 (8)             113 (11)           155 (15)           $< 0.001$
  History of stroke                                                                                                                                                               0.27
   Yes                                                                     26 (0.6)            10 (1.0)                  7 (0.7)            3 (0.3)            6 (0.6)            
   No                                                                      4,146 (99.4)        1,030 (99.0)              1,035 (99.3)       1,041 (99.7)       1,040 (99.4)       
  History of myocardial infarction                                                                                                                                                0.57
   Yes                                                                     58 (1.4)            13 (1.3)                  11 (1.1)           18 (1.7)           16 (1.5)           
   No                                                                      4,114 (98.6)        1,027 (98.7)              1,031 (98.9)       1,026 (98.3)       1,030 (98.5)       

Note: Median (range), $\text{mean} \pm \text{SD}$, or *n* (%) are presented.

Missing data: postmenopausal status $n = 7$, low education level $n = 10$, low physical activity $n = 101$, BMI $n = 3$, waist $n = 3$, pack-years $n = 750$, alcohol consumption $n = 19$, eGFR $n = 65$, and occupation $n = 24$. The missing data were relatively evenly distributed by quartiles of blood lead.

*p*-Value obtained using Kruskal-Wallis *H* test for continuous variables and chi-square test for categorical variables.

Only former and current smokers ($n = 1,744$).

The study participants were 60% women and had a mean age of 57 y (range: 46--67), a mean waist circumference of $83\;{cm}$ (range: 54--152), and a mean BMI of ${26\;{kg}/m}^{2}$ (range: 16--51). About 63% had hypertension, whereas 7.8% had diabetes and 1.4% received statin treatment.

The number of observations with missing covariate data was as follows: postmenopausal status, $n = 7$; low education, $n = 10$; low physical activity, $n = 101$; BMI, $n = 3$; waist, $n = 3$; alcohol consumption, $n = 19$; eGFR, $n = 65$; and occupation, $n = 24$. Ninety one percent (3,807 of 4,172) of the individuals had complete data for all covariates included in the fully adjusted model (Model 3).

Men differed from women in several ways (see Table S1). In particular, men showed higher B-Pb (median $29\;\mu g/L$ in men vs. 22 in women; see Figure S1B), higher prevalence of plaque (39% vs. 33%), and higher prevalence of cardiovascular risk factors. Seventy-four percent of the women were postmenopausal. In comparison with premenopausal women, postmenopausal women had slightly higher B-Pb, and they were on average 9 y older (median B-Pb: $21\;\mu g/L$ vs. $23\;\mu g/L$; mean age: 51 y vs. 60 y in pre- and postmenopausal women, respectively; $p < 0.001$ for both).

Individuals with atherosclerotic plaque in the carotid artery had statistically significantly higher B-Pb levels as well as a higher prevalence of cardiovascular risk factors compared with those without carotid plaque (see Table S2). Specifically, individuals with carotid plaque were older, had a larger waist circumference as well as higher blood pressure and HbA1c levels, were mostly current smokers, and had a higher prevalence of hypertension, diabetes, and statin treatment.

B-Pb was correlated with blood cadmium levels ($r_{s} = 0.22$, $p < 0.001$), waist circumference ($r_{s} = 0.16$, $p < 0.001$), pack-years ($r_{s} = 0.24$, $p < 0.001$), alcohol intake ($r_{s} = 0.38$, $p < 0.001$), systolic ($r_{s} = 0.05$, $p = 0.007$) and diastolic blood pressure ($r_{s} = 0.10$, $p < 0.001$), and total cholesterol/HDL ratio ($r_{s} = 0.05$, $p = 0.005$).

Association between Blood Lead and Plaque {#s3.2}
-----------------------------------------

The prevalence of plaque in the carotid artery was 36% overall, and 10% higher in Q4 than in Q1 ($p < 0.001$) ([Table 1](#t1){ref-type="table"}). [Table 2](#t2){ref-type="table"} shows results from the unadjusted logistic regression model (Model 1); the model adjusted for smoking, waist circumference, hypertension, sex, and age (Model 2); and the model additionally adjusted for total cholesterol/HDL ratio, hsCRP, statin treatment, HbA1c, education level, and physical activity (Model 3). Model 1 showed an increased risk for occurrence of carotid plaque in Q4 as compared with Q1 for all participants as well as for women when stratifying by sex. After adjustment, ORs decreased but remained statistically significant. Overall, in Model 3 Q4 showed a 35% increased OR \[95% confidence interval (CI): 1.09, 1.66\] for plaque in the carotid artery in comparison with Q1 ($p_{\text{trend}} = 0.011$). Among women, those in Q4 had a 58% increased risk (95% CI: 1.20, 2.08) in comparison with Q1 ($p_{\text{trend}} = 0.002$; [Table 2](#t2){ref-type="table"}), whereas there was no such trend in men \[OR for Q4 vs. $Q1 =$ 1.18 (95% CI: 0.83, 1.69), $p_{\text{trend}} = 0.76$\]. The $p_{\text{interaction}}$ between sex and the OR for Q4 was 0.21 (see footnote to [Table 2](#t2){ref-type="table"}). Adjusting Model 1 only for age and sex modified the estimated only slightly (see Table S3).

###### 

Logistic regression models of associations of blood lead (in quartiles) with occurrence of plaque in the carotid artery in the Malmö Diet and Cancer Study--Cardiovascular Cohort (MDCS-CC), in all individuals and stratified by sex.

Table 2 has ten columns. The first column lists quartiles of blood lead (range in micrograms per liter). The adjacent columns list n with plaque percentage, n without plaque percentage, and O R 95 percent C I for models 1, 2, and 3.

                                                          Model 1[^*a*^](#TF6){ref-type="table-fn"}   Model 2[^*b*^](#TF7){ref-type="table-fn"}   Model 3[^*c*^](#TF8){ref-type="table-fn"}                                                                   
  ------------------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ---------- ---------- ------------------- ---------- ---------- -------------------
  All[^*d*^](#TF9){ref-type="table-fn"}                                                                                                                                                                                                                       
   Q1 (1.5--18)                                           317 (30)                                    723 (70)                                    Ref                                         317 (31)   722 (69)   Ref                 295 (31)   669 (69)   Ref
   Q2 (18--25)                                            370 (36)                                    672 (64)                                    1.26 (1.05, 1.51)                           370 (36)   672 (64)   1.18 (0.97, 1.43)   338 (36)   611 (64)   1.19 (0.97, 1.46)
   Q3 (25--33)                                            368 (35)                                    676 (65)                                    1.24 (1.03, 1.49)                           367 (35)   676 (65)   1.11 (0.91, 1.35)   333 (35)   618 (65)   1.13 (0.92, 1.39)
   Q4 (33--258)                                           427 (41)                                    619 (59)                                    1.57 (1.31, 1.88)                           426 (41)   619 (59)   1.31 (1.07, 1.59)   379 (40)   564 (60)   1.35 (1.09, 1.66)
  $p_{\text{trend}}$[^*e*^](#TF10){ref-type="table-fn"}                                                                                           $< 0.001$                                                         0.018                                     0.011
  Women[^*d*^](#TF9){ref-type="table-fn"}                                                                                                                                                                                                                     
   Q1 (1.5--18)                                           234 (29)                                    579 (71)                                    Ref                                         234 (29)   578 (71)   Ref                 217 (29)   535 (71)   Ref
   Q2 (18--25)                                            227 (33)                                    467 (67)                                    1.20 (0.97, 1.50)                           227 (33)   467 (67)   1.14 (0.91, 1.44)   206 (32)   429 (68)   1.13 (0.89, 1.44)
   Q3 (25--33)                                            190 (33)                                    382 (67)                                    1.23 (0.98, 1.55)                           190 (33)   382 (67)   1.11 (0.87, 1.41)   171 (33)   353 (67)   1.13 (0.87, 1.45)
   Q4 (33--258)                                           180 (41)                                    262 (59)                                    1.70 (1.33, 2.17)                           180 (41)   262 (59)   1.50 (1.16, 1.94)   158 (40)   235 (60)   1.58 (1.20, 2.08)
  $p_{\text{trend}}$[^*e*^](#TF10){ref-type="table-fn"}                                                                                           $< 0.001$                                                         0.004                                     0.002
  Men[^*d*^](#TF9){ref-type="table-fn"}                                                                                                                                                                                                                       
   Q1 (2.7--18)                                           83 (37)                                     144 (63)                                    Ref                                         83 (37)    144 (63)   Ref                 78 (37)    134 (63)   Ref
   Q2 (18--25)                                            143 (41)                                    205 (59)                                    1.21 (0.86, 1.71)                           143 (41)   205 (59)   1.22 (0.85, 1.76)   132 (42)   182 (58)   1.32 (0.90, 1.94)
   Q3 (25--33)                                            178 (38)                                    294 (62)                                    1.05 (0.76, 1.46)                           177 (38)   294 (62)   1.06 (0.75, 1.50)   162 (38)   265 (62)   1.11 (0.77, 1.60)
   Q4 (33--173)                                           247 (41)                                    357 (59)                                    1.20 (0.88, 1.64)                           246 (41)   357 (59)   1.13 (0.81, 1.58)   221 (40)   329 (60)   1.18 (0.83, 1.69)
  $p_{\text{trend}}$[^*e*^](#TF10){ref-type="table-fn"}                                               0.39                                                                                               0.82                                      0.76       

Note: $p_{\text{Interaction}}$ term of $Q4 \times \text{sex}$ in $\text{Model\  }3\text{ \ with\  \ all\  \ individuals} = 0.21$. CI, confidence interval; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; OR, odds ratio; Q, quartile; Ref, reference.

Model 1: Unadjusted.

Model 2: Adjusted for smoking, waist circumference, hypertension, sex, and age.

Model 3: Additionally adjusted for total cholesterol/HDL ratio, C-reactive protein, statin treatment, HbA1c, education level, and physical activity.

Model 1: $n = 4,172$ (all), $n = 2,521$ (women), $n = 1,651$ (men); Model 2: $n = 4,169$ (all), $n = 2,520$ (women), $n = 1,649$ (men); Model 3: $n = 3,807$ (all), $n = 2,304$ (women), $n = 1,503$ (men).

Linear trend *p*-values were derived by modeling the median value of each blood lead quartile as a continuous variable in the models.

When the statistical analyses were stratified by smoking status, ORs became weaker and nonsignificant for never smokers \[OR for Q4 vs. $Q1 =$ 1.14 (95% CI: 0.81, 1.61)\], whereas they were stronger and significant for ever smokers \[OR for Q4 vs. $Q1 =$ 1.61 (95% CI: 1.23, 2.12), $p_{\text{trend}} = 0.002$, $p_{\text{interaction}} = 0.10$; [Table 3](#t3){ref-type="table"}\]. When stratifying by menopausal status, postmenopausal women ($n = 1,695$ with complete data on covariates) showed an increased risk \[OR for Q4 vs. $Q1 =$ 1.72 (95% CI: 1.26, 2.34), $p_{\text{trend}} = 0.001$; [Figure 2](#f2){ref-type="fig"} and [Table 3](#t3){ref-type="table"}\]. The $p_{\text{interaction}}$ between menopausal status and quartiles of B-Pb (Q4 compared with Q1) was 0.11. We found no associations between B-Pb and risk of atherosclerosis in premenopausal women \[$n = 603$; OR for Q4 vs. $Q1 =$ 0.96 (95% CI: 0.49, 1.89)\]. Stratification of Model 3 by hypertension showed similar risks in individuals with and without hypertension ($p_{\text{interaction}} = 0.82$; [Table 3](#t3){ref-type="table"}).

###### 

Logistic regression models (Model 3 from [Table 2](#t2){ref-type="table"}) of associations of blood lead (in quartiles) with occurrence of carotid plaque in the Malmö Diet and Cancer Study--Cardiovascular Cohort (MDCS-CC) stratified by characteristics (smoking status, hypertension, menopausal status, and eGFR).

Table 3 has six columns. The first column lists blood lead range in micrograms per liter. The adjacent columns list quartiles of blood lead in q1, 2, 3, and 4. The final column mentions p for trend superscript a.

  Characteristics                                                         Quartiles of blood lead   $p_{\text{Trend}}$[^*a*^](#TF12){ref-type="table-fn"}                                           
  ----------------------------------------------------------------------- ------------------------- ------------------------------------------------------- ------------------- ------------------- -------
  Blood lead \[range ($\mu g/L$)\]                                        1.5--18                   18--25                                                  25--33              33--258             
  Smoking status[^*b*^](#TF13){ref-type="table-fn"}                                                                                                                                                 
   Never smokers ($n = 1,561$)                                                                                                                                                                      
    *n* with plaque                                                       144                       139                                                     106                 87                  
    *n* without plaque                                                    355                       310                                                     228                 192                 
    OR (95% CI)                                                           1.0                       1.06 (0.80, 1.42)                                       1.14 (0.83, 1.57)   1.14 (0.81, 1.61)   0.40
   Ever smokers ($n = 2,246$)                                                                                                                                                                       
    *n* with plaque                                                       151                       199                                                     227                 292                 
    *n* without plaque                                                    314                       301                                                     390                 372                 
    OR (95% CI)                                                           1.0                       1.39 (1.05, 1.84)                                       1.20 (0.91, 1.58)   1.61 (1.23, 2.12)   0.002
  Hypertension[^*c*^](#TF14){ref-type="table-fn"}                                                                                                                                                   
   No ($n = 1,444$)                                                                                                                                                                                 
    *n* with plaque                                                       78                        105                                                     92                  94                  
    *n* without plaque                                                    290                       282                                                     285                 218                 
    OR (95% CI)                                                           1.0                       1.25 (0.88, 1.79)                                       1.12 (0.77, 1.61)   1.48 (1.01, 2.16)   0.071
   Yes ($n = 2,363$)                                                                                                                                                                                
    *n* with plaque                                                       217                       233                                                     241                 285                 
    *n* without plaque                                                    379                       329                                                     333                 346                 
    OR (95% CI)                                                           1.0                       1.16 (0.90, 1.48)                                       1.17 (0.91, 1.50)   1.30 (1.01, 1.68)   0.053
  Menopausal status[^*d*^](#TF15){ref-type="table-fn"}                                                                                                                                              
   Premenopausal women ($n = 603$)                                                                                                                                                                  
    *n* with plaque                                                       38                        31                                                      21                  17                  
    *n* without plaque                                                    188                       125                                                     113                 70                  
    OR (95% CI)                                                           1.0                       1.08 (0.63, 1.88)                                       0.77 (0.42, 1.42)   0.96 (0.49, 1.89)   0.69
   Postmenopausal women ($n = 1,695$)                                                                                                                                                               
    *n* with plaque                                                       178                       175                                                     149                 141                 
    *n* without plaque                                                    345                       304                                                     239                 164                 
    OR (95% CI)                                                           1.0                       1.14 (0.87, 1.49)                                       1.19 (0.90, 1.59)   1.72 (1.26, 2.34)   0.001
  eGFR categories[^*e*^](#TF16){ref-type="table-fn"}                                                                                                                                                
   eGFR $> 90\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ ($n = 602$)                                                                                                                                
    *n* with plaque                                                       34                        46                                                      38                  54                  
    *n* without plaque                                                    122                       95                                                      99                  114                 
    OR (95% CI)                                                           1.0                       1.51 (0.85, 2.69)                                       1.15 (0.63, 2.09)   1.27 (0.71, 2.28)   0.72
   eGFR $60–90\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ ($n = 2,761$)                                                                                                                             
    *n* with plaque                                                       230                       229                                                     252                 285                 
    *n* without plaque                                                    476                       432                                                     454                 403                 
    OR (95% CI)                                                           1.0                       1.06 (0.83, 1.34)                                       1.05 (0.83, 1.33)   1.25 (0.98, 1.59)   0.07
   eGFR $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$($n = 414$)                                                                                                                                 
    *n* with plaque                                                       30                        60                                                      39                  36                  
    *n* without plaque                                                    68                        78                                                      60                  43                  
    OR (95% CI)                                                           1.0                       1.79 (1.00, 3.19)                                       1.53 (0.83, 2.84)   2.16 (1.10, 4.24)   0.06

Note: Model 3 from [Table 2](#t2){ref-type="table"}: Adjusted for sex, age, waist circumference, total cholesterol/HDL ratio, C-reactive protein, statin treatment, HbA1c, education level, physical activity, and when appropriate also for smoking and hypertension. Complete case analyses based on $n = 3,807$ (men and women), except for the model stratified for menopausal status ($n = 2,298$ women with complete data for all covariates and menopausal status) and for eGFR categories ($n = 3,777$ men and women with complete data for all covariates and eGFR). CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; OR, odds ratio; Q, quartile.

Linear trend *p*-values were derived by modeling the median value of each blood lead quartile as a continuous variable in the models.

$p_{\text{Interaction}}$ term of $Q4 \times \text{ever\  \ smokers}$ in $\text{Model\  }3\text{ \ with\  \ all\  \ individuals} = 0.10$.

$p_{\text{Interaction}}$ term of $Q4 \times \text{hypertension}$ in $\text{Model\  }3\text{ \ with\  \ all\  \ individuals} = 0.82$.

$p_{\text{Interaction}}$ term of $Q4 \times \text{postmenopausal}$ status in $\text{Model\  }3\text{ \ with\  \ all\  \ individuals} = 0.11$.

$p_{\text{Interaction}}$ term of $Q4 \times \text{eGFR}$ $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ in $\text{Model\  }3\text{ \ with\  \ all\  \ individuals} = 0.48$.

![Odds ratios for atherosclerotic plaque associated with blood lead concentrations (quartiles Q1--Q4) in women by menopausal status ($n = 603$ premenopause, $n = 1,695$ postmenopause), adjusted for smoking, waist circumference, total cholesterol/HDL ratio, hypertension, age, CRP, statin treatment, HbA1c, education level, and physical activity. Vertical lines indicate 95% confidence intervals. $p_{\text{Interaction}}$ for Q4 vs. Q1 was 0.11. Note: CRP, C-reactive protein; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein.](ehp-127-127002-g002){#f2}

Stratifying Model 3 by eGFR showed strongest estimates for individuals with decreased kidney function. In individuals with eGFR $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$, the OR for Q4 vs. $Q1 =$ 2.16 \[(95% CI: 1.10, 4.24), $n = 414$, $p_{\text{trend}} = 0.06$\]. In individuals with eGFR $60–90\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ the OR for Q4 vs. $Q1 =$ 1.25 \[(95% CI: 0.98, 1.59), $n = 2,761$, $p_{\text{trend}} = 0.07$\], and in individuals with eGFR $> 90\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$, the OR for Q4 vs. $Q1 =$ 1.27 \[(95% CI: 0.71, 2.28), $n = 602$, $p_{\text{trend}} = 0.72$; [Table 3](#t3){ref-type="table"} and Figure S2\].

Introducing a quadratic term of the B-Pb concentrations in Model 3 to assess nonlinearity did not show evidence of nonlinearity ($p = 0.16$). This is consistent with [Figure 3](#f3){ref-type="fig"}, showing a linear association in the smoothed exposure--response relation for carotid plaque based on B-Pb as a continuous variable ([Figure 3](#f3){ref-type="fig"} for $B\text{-}{Pb} < 150\;\mu g/L$; see Figure S3 for all individuals). The smoothed exposure--response relation in men and women separately are consistent with the findings in [Table 2](#t2){ref-type="table"} (see Figure S4A for men and S4B for women). Log-transformation of B-Pb showed no influence of extreme values on the association between B-Pb and atherosclerosis (see Figure S5).

![Smooth function (with 95% confidence interval) describing the impact of blood lead (B-Pb) (below $150\;\mu g/L$, $n = 4,170$) on the risk of atherosclerosis. Model adjusted for smoking, waist circumference, total cholesterol/HDL ratio, hypertension, age, sex, CRP, statin treatment, HbA1c, education level and physical activity (Model 3 from [Table 2](#t2){ref-type="table"}). Individual values of B-Pb are indicated on the *x*-axis and arrows indicate medians of B-Pb within quartiles. Log(odds) relabeled to odds ratios are presented. Note: CRP, C-reactive protein; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein.](ehp-127-127002-g003){#f3}

Sensitivity Analyses {#s3.3}
--------------------

Adjusting the statistical models for pack-years in those individuals with data available and using five categories as described above instead of smoking categories showed essentially the same results concerning associations between B-Pb and atherosclerosis in all individuals as well as in men and women separately (see Table S4). We also tested the influence of kidney function by adjusting the models for creatinine-based eGFR, but the estimates remained unchanged (see Table S5). We also examined whether the estimates from Model 3 changed by introducing blood cadmium in the model, but ORs remained essentially unchanged (see Table S6). We adjusted Model 3 also for occupation (blue-collar, white-collar, and self-employed workers) and for diabetes (instead of HbA1c), but these additional adjustments did not change the estimates (see Tables S7 and S8). Adjusting Model 3 for BMI instead of waist circumference showed essentially the same results (see Table S9).

When we stratified Model 3 by age ($<$ and $\geq 55\; y$), associations were stronger among individuals $> 55$ years of age as compared with those $< 55$ years of age among both men and women together \[OR for Q4 vs. $Q1 =$ 1.45 (95% CI: 1.13, 1.85) in those $> 55$ years of age, and OR for Q4 vs. $Q1 =$ 1.08 (95% CI: 0.72, 1.85) in those $< 55$ years of age\] as well as among men \[$\text{OR} =$ 1.23 (95% CI: 0.81, 1.88) and $\text{OR} =$ 1.04 (95% CI: 0.52, 2.07), respectively\] and women \[$\text{OR} =$ 1.74 (95% CI: 1.26, 2.40) and $\text{OR} =$ 1.10 (95% CI: 0.63, 1.94), respectively\], separately (see Table S10).

When we ran the analyses with B-Pb as a continuous variable rather than in quartiles, every $10\text{-}\mu g/L$ increase in B-Pb was associated with a 12% higher risk (95% CI: 1.05, 1.19) of atherosclerotic plaque in women and 5% higher risk in both men and women together (95% CI: 0.99, 1.10), whereas there was no association among men \[$\text{OR} =$0.98 (95% CI: 0.91, 1.05)\]. When we stratified by postmenopausal status, every $10\text{-}\mu g/L$ increase in B-Pb was associated with an 18% higher risk (95% CI: 1.09, 1.27) among postmenopausal women, whereas there was no association among premenopausal women \[$\text{OR} =$ 0.95 (95% CI: 0.78, 1.13)\].

Finally, we excluded all individuals with B-Pb above $100\;\mu g/L$ ($n = 8$ men and $n = 7$ women) to test whether the associations found between B-Pb (as a continuous variable) and risk of atherosclerosis were driven by individuals with extreme values. The results were essentially the same for all individuals \[$\text{OR} =$ 1.06 (95% CI: 1.002, 1.12)\] as well as for women \[$\text{OR} =$1.12 (95% CI: 1.04, 1.21)\] and men \[$\text{OR} =$1.001 (95% CI: 0.92, 1.08)\] separately (see Table S11).

Discussion {#s4}
==========

Our study, based on a large Swedish population-based cohort, supports the hypothesis that environmental lead exposure is an important risk factor for atherosclerosis. After controlling for known risk factors and confounders, individuals in the highest quartile of B-Pb (median: $42\;\mu g/L$; range: 33--258) had a 35% (95% CI: 9, 66%) higher risk of atherosclerosis compared with those in the lowest quartile (median: $15\;\mu g/L$; range: 1.5--18). In men, there was a nonsignificant 18% (95% CI: $–17$, 69%) increase in OR, whereas the associations were stronger for women, who showed a 58% (95% CI: 20, 108%) increased risk in the highest quartile of B-Pb compared with the lowest quartile. However, among women, the association between B-Pb and plaque was limited to postmenopausal women; OR for Q4 vs. $Q1 =$ 1.72 (95% CI: 1.26, 2.34) vs. OR for Q4 vs. $Q1 =$ 0.96 (95% CI: 0.49, 1.89) in premenopausal women. Individuals with decreased kidney function (eGFR $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$, $n = 414$) had a higher risk of atherosclerosis as compared with those with normal kidney function.

As discussed in several reviews and reports ([@c11]; [@c33]; [@c36]; [@c47]), a number of studies have shown associations between environmental lead exposure and cardiovascular disease and mortality in cohorts with low-level lead exposure (B-Pb concentrations $< 50\;\mu g/L$). Five American studies on low-level environmental lead exposure (NHANES data) showed consistent associations between B-Pb concentrations and cardiovascular mortality ([@c23]; [@c26]; [@c28]; [@c42]; [@c43]). An increased risk of cardiovascular mortality has also been found at high levels of lead exposure in several occupational cohorts ([@c33]; [@c46]). Concerning nonfatal clinical cardiovascular outcomes, three American studies based on NHANES cohorts showed an association between low-level lead exposure and peripheral arterial disease ([@c19]; [@c31]; [@c34]), whereas another study using lead concentrations in urine (a less reliable biomarker of lead exposure) showed no associations ([@c35]). The systematic review by Chowdhury et al. ([@c9]) identified only two prospective studies on environmental lead exposure and coronary artery disease or stroke: one British and one Danish ([@c29]; [@c39]). These prospective studies found little support of associations between B-Pb concentrations and coronary heart disease after adjustment for confounders ([@c29]; [@c39]). In contrast, an American study based on the Normative Aging Study cohort reported an increased incidence of coronary heart disease \[$\text{Hazard\  \ ratio} =$1.73 (95% CI: 1.05, 2.87)\] among individuals with B-Pb $\geq 50\;\mu g/L$ vs. $< 50\;\mu g/L$, even after adjustment for risk factors and confounders ([@c22]). Finally, a study in Chinese adults reported no significant trend between plasma lead levels and incident coronary heart disease using plasma lead modeled by quartiles ([@c54]), but plasma lead is rarely used as a biomarker for lead exposure. The level of lead in plasma is usually $< 1\%$ of that in whole blood and the plasma levels in the study by Yuan et al. ([@c54]) were much higher than what can be expected in a population study ([@c21]; [@c46]).

Cardiovascular disease continues to be the leading cause of death and the main contributor to premature mortality worldwide ([@c17]). In particular, coronary heart disease and cerebrovascular disease together account for about 15 million deaths globally every year ([@c17]). Lead exposure has been estimated to account for 2% of the total cardiovascular disease burden worldwide (nearly 240,000 deaths yearly), suggesting lead to be an important cardiovascular risk factor ([@c16]). Taking into account that lead exposure is widespread and that 41% of all individuals in the highest quartile of B-Pb had atherosclerotic plaque in the carotid artery, the results in the present study are relevant for public health.

In our study, the association was limited to postmenopausal women with those in the highest quartile of B-Pb showing a 72% higher risk of plaque (95% CI: 1.26, 2.34) in comparison with those in the lowest quartile. In premenopausal women the corresponding OR was 0.96 (95% CI: 0.49, 1.89). However, when we examined the associations between B-Pb and plaque among men and women by age ($<$ and $\geq 55\; y$), estimates were somewhat stronger also among men in the older group as compared with the younger group, although nonsignificant for men. Therefore, we cannot rule out that the associations found among postmenopausal women are partially driven by age. Few studies have examined lead-related cardiovascular risks in postmenopausal women. Nash et al. ([@c32]) found an increasing risk of diastolic hypertension with increasing quartiles of B-Pb in postmenopausal women, whereas another small study found no associations ([@c2]). Menopause is known to involve increased bone demineralization, meaning that lead stored in bone may enter the blood stream at a higher rate and thus increase the circulating lead concentrations and thereby the endogenous lead exposure ([@c45]; [@c50]). However, the postmenopausal women in our study showed only slightly higher B-Pb concentrations (median $23\;\mu g/L$) compared with premenopausal women ($21\;\mu g/L$; $p < 0.001$). Thus, if our finding regarding effect modification by menopause is valid (the numbers of premenopausal women per quartile were limited), it may be due to other factors that are more prevalent throughout this period of life, rather than solely a higher endogenous lead exposure. Both vascular endothelial dysfunction (VED) and large artery stiffness are known to accelerate during menopause, presumably as consequences of a declining ovarian function and decreased estrogen levels ([@c30]). The faster progression of VED during menopause has been associated with a decreased availability of nitric oxide as well as an up-regulation of pro-inflammatory cytokines: two mechanisms that have been associated with lead exposure ([@c52]).

Several mechanisms have been suggested to underlie lead-induced cardiotoxicity ([@c52]). Cellular and molecular mechanisms such as oxidative stress, increased lipid peroxidation, impairment of the renin--angiotensin system, endothelial injury with reduced endothelial cell growth, and stimulation of the vascular smooth muscle cell proliferation have been shown experimentally. Interestingly, low-level lead exposure has been associated with increased pulse pressure, suggesting the involvement of lead in the pathogenesis of arterial stiffness ([@c37]). Large artery stiffness has been attributed to structural alterations in the arterial wall such as increased collagen and decreased elastin but also to functional alterations related to a decreased nitric oxide availability ([@c30]). In turn, increased artery stiffness has been associated with a higher prevalence of atherosclerosis, independent of other cardiovascular risk factors ([@c56]). An *in vitro* study showed that lead levels of $0.5–10\;\mu M$ induced proliferation of vascular smooth cells and fibroblasts ([@c14]). In another study, Zeller et al. ([@c55]) found that lead was absorbed by human endothelial cells (ECs) and smooth muscle cells (SMCs). Lead caused proliferation of ECs and up-regulation of cellular stress proteins (heme oxygenase-1, heat shock protein 7, and 4-nitroquinoline 1-oxide) and increased secretion of IL-8. This stimulated the invasion of SMCs into the intima and intima thickening, as demonstrated in a human arterial organ culture. In addition, lead stimulated elastin synthesis in SMCs, which is of interest because elastic fibers are primary sites for lipid deposition. These findings suggest mechanisms whereby lead may be involved in the initiation phase of atherosclerosis ([@c55]).

In humans, evidence on low-level lead toxicity in the cardiovascular system is particularly extensive for hypertension, which is an important risk factor for cardiovascular disease ([@c33]; [@c36]; [@c51]). However, limited data are available on associations between lead exposure in the general population and atherosclerosis, a key mechanism in cardiovascular disease. We found three studies investigating the relation between B-Pb concentrations and ankle--brachial index (ABI), an indirect measure of atherosclerosis in the lower extremities ([@c19]; [@c31]; [@c34]). In all three studies, B-Pb concentrations were associated with peripheral artery disease (ABI $< 0.9$). Although there is some evidence from experimental studies linking lead exposure to atherosclerosis, to our knowledge, only one epidemiological study has investigated the association between environmental lead exposure and atherosclerotic plaques in the carotid arteries ([@c25]). The latter study was performed in 1,016 elderly individuals and found no significant association with B-Pb. The present epidemiological study is the first to show an association between B-Pb and the risk of atherosclerosis in the carotid arteries.

Individuals with impaired renal function might be a susceptible population at risk of cardiovascular effects of lead. Reduced kidney function could lead to a less efficient elimination of lead due to a reduced renal clearance, with increased B-Pb concentrations as a consequence ([@c36]). This could in turn increase the risk of developing atherosclerosis earlier. In the present study, however, blood concentrations in individuals with decreased kidney function defined as eGFR $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ (median B-Pb: 23.5; range: 6.1--173) did not differ statistically from those in individuals with normal kidney function (median: 24.2; range: 1.5--258; $p = 0.20$). Moreover, adjusting the statistical models for eGFR did not affect the estimates. Nonetheless, reduced kidney function is well known to be associated with higher cardiovascular risk ([@c3]; [@c18]). In our study, individuals in the highest quartile of B-Pb with eGFR $< 60\;{mL}/\text{min\  \ per\  }1.73{\, m}^{2}$ had a higher risk of developing atherosclerosis \[$\text{OR} =$ 2.16 (95% CI: 1.10, 4.24)\] compared with those with normal kidney function, but this was based on few individuals and results should, therefore, be interpreted with caution. However, the relation between lead exposure and kidney function is complex. Apart from the potential impact of GFR on B-Pb levels, the reverse may also be the case, that is, that lead exposure may cause kidney damage. This has been shown also in prospective studies, including a recent one based on the present cohort ([@c20]). Here we used serum creatinine to estimate GFR. Combined creatinine/cystatin C equations may be superior ([@c49]), but in the present cohort the impact of B-Pb on the longitudinal change of eGFR was similar for the creatinine equation and the combined equation ([@c20]).

Environmental exposure to lead remains a public health problem. Although lead exposure has decreased considerably in recent years ([@c46]), it still occurs via contaminated food and drinking water, smoking, and inhalation of polluted air in areas with heavy traffic or industrial emissions ([@c11]; [@c46]). As a consequence, there are still reports of health effects in children and adults even at low levels of lead exposure ([@c36]; [@c46]). B-Pb concentrations in the present study ranged from 1.5 to $258\;\mu g/L$ (median: 25), which is in line with those reported in other studies on environmental lead exposure ([@c1]; [@c8]; [@c10]; [@c48]; [@c49]; [@c53]), but much lower than in occupational settings ([@c33]; [@c46]). The associations between B-Pb and risk of atherosclerosis in our study were found in individuals in the highest quartile of B-Pb (median: $42\;\mu g/L$; range: 33--258), which is higher than the levels at which associations with peripheral artery disease were found in the NHANES studies ([@c19]; [@c31]; [@c34]). The associations remained essentially the same after excluding individuals with B-Pb $> 100\;\mu g/L$.

The present study has several strengths and limitations. Strengths include the large number of participants (although the numbers were small in some stratified analyses), the high analytical accuracy of the B-Pb analyses, and the standardized ultrasound technique. Another strength was the possibility to adjust the statistical models for the main known cardiovascular risk factors and potential confounders. This study also has limitations. For example, due to the cross-sectional study design, we cannot infer the temporal relation between exposure and the outcome. In addition, we used a single measurement of B-Pb as a measure of lead exposure, and it is likely that B-Pb for many of the participants had been higher before the early 1990s when they were recruited ([@c12]). Therefore, we cannot exclude the possibility that development of atherosclerosis in the study participants was at least partly due to higher lead exposure earlier in life. Bone lead, which was not available, would have been a better biomarker of long-term cumulative lead exposure. B-Pb has a half-life of about 1 month after end of exposure, so if exposure suddenly increases or decreases, this will affect B-Pb levels. At a stable exposure it will, however, reflect the body burden. We did not have complete data on pack-years for all individuals, and therefore used smoking status (never or ever smoker) instead. Nevertheless, sensitivity analyses adjusted for pack-years showed essentially the same results as those adjusted for smoking status. We did not include dietary factors among potential confounders adjusted for, but a proxy of overall energy intake should be covered by the inclusion of waist circumference. Regarding fiber, fish, fruit and vegetables, we do not consider them related to lead intake. Another limitation is the use of only the presence of plaque as outcome. Other measurements such as the plaque size or plaque burden would have been useful measurements of the degree of atherosclerosis. Such measurements were, however, not done in a consistent way in the early 1990s when the study recruitment was performed.

In conclusion, our study shows an association between lead exposure and the occurrence of atherosclerotic plaque in the carotid artery, adding evidence to an underlying pro-atherogenic role of lead in cardiovascular disease.
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